Breaking News Instant updates and real-time market news.

CLVS

Clovis

$29.16

-0.205 (-0.70%)

08:07
10/02/18
10/02
08:07
10/02/18
08:07

Clovis receives Breakthrough Therapy Designation for Rubraca

Clovis Oncology announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for Rubraca as a monotherapy treatment of adult patients with BRCA1/2-mutated mCRPC who have received at least one prior androgen receptor-directed therapy and taxane-based chemotherapy. Breakthrough Therapy designation is granted by the FDA to investigational agents intended to treat a serious or life-threatening disease or condition and whose preliminary clinical evidence may demonstrate substantial improvement on at least one clinically significant endpoint over available therapy. The FDA previously granted Breakthrough Therapy designation to Rubraca for the monotherapy treatment of certain advanced ovarian cancer patients and then in December 2016 approved Rubraca for the treatment of certain adult patients with deleterious BRCA mutation associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. The FDA subsequently approved Rubraca in a second indication, the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, in April 2018. This most recent Breakthrough Therapy designation was granted to Rubraca based on initial efficacy and safety results from TRITON2, the Phase 2 study of Rubraca in men with advanced prostate cancer with BRCA 1/2 mutations and deleterious mutations of other homologous recombination repair genes, in the metastatic castration-resistant setting.

CLVS Clovis
$29.16

-0.205 (-0.70%)

09/17/18
PIPR
09/17/18
NO CHANGE
Target $35
PIPR
Neutral
Piper sees Astra's Lynparza as 'much cleaner' than Tesaro's Zejula
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $35 price target on Tesaro (TSRO) after analyzing a year's worth of adverse event reporting as captured by FDA's Adverse Event Reporting System database, which he obtained through a Freedom of Information Act request. The analyst, while cautioning that the database "likely contains inaccuracies and is far from perfect," is "struck by how much cleaner" AstraZeneca's (AZN) Lynparza appears versus Tesaro's Zejula and Clovis Oncology's (CLVS) Rubraca. Further, Raymond is also surprised that Zejula's adverse events rates do not appear to have decreased in any meaningful way year-over-year, despite Tesaro's active down-dosing efforts. Since the analyst thinks PARPi differentiation remains largely around safety, he lowered his Zejula estimates in 2019 and beyond. Lynparza is likely to maintain the upper hand, Raymond tells investors in a research note.
09/17/18
GUGG
09/17/18
INITIATION
Target $75
GUGG
Buy
Clovis initiated with a Buy at Guggenheim
Target $75.
09/21/18
JPMS
09/21/18
NO CHANGE
Target $71
JPMS
Overweight
Clovis price target lowered to $71 from $87 at JPMorgan
JPMorgan analyst Cory Kasimov lowered his price target for Clovis Oncology to $71 after "reigning in" his ovarian expectations but keeps an Overweight rating on the shares. With the European Society of Medical Oncology meeting coming up in October, Kasimov is previewing the first look at data from Clovis's Triton-2 study in prostate cancer. The analyst is "quite confident" that the company's PARP inhibitor rucaparib should produce response rates that are well above chemotherapy and anti-androgens, at least in third line BRCA positive patients. He views the Triton-2 update as an important event for Clovis and believes "promising results could represent a step towards restoring more favorable sentiment." A response rate of at least 30% is the lower bar for share appreciation, Kasimov tells investors in a research note. He keeps an Overweight rating on Clovis.
09/24/18
LEER
09/24/18
INITIATION
Target $30
LEER
Market Perform
Clovis initiated with a Market Perform at Leerink
Leerink analyst Andrew Berens started Clovis Oncology with a Market Perform rating and $30 price target.

TODAY'S FREE FLY STORIES

F

Ford

$8.41

0.055 (0.66%)

15:40
10/22/18
10/22
15:40
10/22/18
15:40
Options
Ford option volume is 2X daily average ahead of earnings »

Ford option volume is 2X…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 13

    Dec

SCG

Scana

$36.75

-4.14 (-10.12%)

15:39
10/22/18
10/22
15:39
10/22/18
15:39
Hot Stocks
Breaking Hot Stocks news story on Scana 

SCANA trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETX

Aratana Therapeutics

$5.20

-0.15 (-2.80%)

15:38
10/22/18
10/22
15:38
10/22/18
15:38
Periodicals
Aratana Therapeutics exploring strategic alternatives, Dealreporter says »

Aratana Therapeutics,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

LOGI

Logitech

$40.00

0.88 (2.25%)

15:34
10/22/18
10/22
15:34
10/22/18
15:34
Options
Logitech options imply 10.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

LLY

Eli Lilly

$111.85

-0.06 (-0.05%)

15:32
10/22/18
10/22
15:32
10/22/18
15:32
Hot Stocks
Eli Lilly announces 'positive' results for two Phase 3 studies of Taltz »

Eli Lilly announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

SCG

Scana

$36.46

-4.43 (-10.83%)

, D

Dominion

$73.31

-0.215 (-0.29%)

15:27
10/22/18
10/22
15:27
10/22/18
15:27
Hot Stocks
SCANA says SC judge indicated no final decision has been reached »

SCANA issued the…

SCG

Scana

$36.46

-4.43 (-10.83%)

D

Dominion

$73.31

-0.215 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 11

    Nov

  • 11

    Nov

15:25
10/22/18
10/22
15:25
10/22/18
15:25
Conference/Events
UBS LatAm Equity Research Analyst to hold an analyst/industry conference call »

LatAm Equity…

NKTR

Nektar

$40.00

-8.23 (-17.06%)

, RHHBY

Roche

$0.00

(0.00%)

15:24
10/22/18
10/22
15:24
10/22/18
15:24
Hot Stocks
Nektar Therapeutics plunges as Roche data seen as concern »

Shares of Nektar…

NKTR

Nektar

$40.00

-8.23 (-17.06%)

RHHBY

Roche

$0.00

(0.00%)

LLY

Eli Lilly

$111.88

-0.03 (-0.03%)

BMY

Bristol-Myers

$50.90

-3.41 (-6.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 24

    Dec

  • 20

    May

SCG

Scana

$36.13

-4.76 (-11.64%)

15:20
10/22/18
10/22
15:20
10/22/18
15:20
Hot Stocks
Breaking Hot Stocks news story on Scana »

SCANA trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$130.96

-0.41 (-0.31%)

15:20
10/22/18
10/22
15:20
10/22/18
15:20
Options
Second day of interest in Caterpillar weekly puts ahead of earnings »

Second day of interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SLM

Sallie Mae

$10.57

-0.01 (-0.09%)

15:19
10/22/18
10/22
15:19
10/22/18
15:19
Options
Sallie Mae options imply 6.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/22/18
10/22
15:17
10/22/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/22/18
10/22
15:16
10/22/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$127.64

4.15 (3.36%)

15:15
10/22/18
10/22
15:15
10/22/18
15:15
Options
Ralph Lauren put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

15:15
10/22/18
10/22
15:15
10/22/18
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

AJG

Arthur J. Gallagher

$72.68

-0.005 (-0.01%)

15:10
10/22/18
10/22
15:10
10/22/18
15:10
Hot Stocks
Arthur J. Gallagher acquires Richter International Consulting, terms undisclosed »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 02

    Nov

  • 14

    Nov

UBSFY

Ubisoft

$0.00

(0.00%)

, EA

Electronic Arts

$101.96

-0.11 (-0.11%)

15:07
10/22/18
10/22
15:07
10/22/18
15:07
Periodicals
EA Motive founder Raymond to leave company, VentureBeat reports »

EA Motive (EA) studio…

UBSFY

Ubisoft

$0.00

(0.00%)

EA

Electronic Arts

$101.96

-0.11 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

VAR

Varian Medical

$103.96

-0.285 (-0.27%)

15:06
10/22/18
10/22
15:06
10/22/18
15:06
Conference/Events
Varian Medical to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CDNS

Cadence Design

$40.68

0.55 (1.37%)

15:04
10/22/18
10/22
15:04
10/22/18
15:04
Options
Cadence Design options imply 7.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 12

    Mar

FDC

First Data

$23.19

-0.22 (-0.94%)

15:03
10/22/18
10/22
15:03
10/22/18
15:03
Hot Stocks
First Data to refinance revolving credit facility and certain other indebtedness »

First Data announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 03

    Mar

CSBR

Champions Oncology

$12.10

-0.61 (-4.80%)

15:00
10/22/18
10/22
15:00
10/22/18
15:00
Conference/Events
Champions Oncology management to meet with Craig-Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 15

    Nov

SCG

Scana

$36.09

-4.8 (-11.74%)

, D

Dominion

$73.39

-0.135 (-0.18%)

14:57
10/22/18
10/22
14:57
10/22/18
14:57
Periodicals
SC senator: Law on nuclear construction to be deemed unconstitutional, CBJ says »

South Carolina state…

SCG

Scana

$36.09

-4.8 (-11.74%)

D

Dominion

$73.39

-0.135 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 11

    Nov

  • 11

    Nov

SCG

Scana

$36.43

-4.46 (-10.91%)

, D

Dominion

$73.29

-0.235 (-0.32%)

14:55
10/22/18
10/22
14:55
10/22/18
14:55
Periodicals
Breaking Periodicals news story on Scana, Dominion »

Dominion declines comment…

SCG

Scana

$36.43

-4.46 (-10.91%)

D

Dominion

$73.29

-0.235 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 11

    Nov

  • 11

    Nov

SYMC

Symantec

$19.73

0.06 (0.31%)

14:50
10/22/18
10/22
14:50
10/22/18
14:50
Options
Sweep buyer of Symantec call options »

Sweep buyer of Symantec…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 01

    Nov

  • 06

    Dec

AMTD

TD Ameritrade

$50.05

-0.44 (-0.87%)

14:49
10/22/18
10/22
14:49
10/22/18
14:49
Options
TD Ameritrade options imply 5.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.